The mission of the CGC.nl consortium (www.cancergenomics.nl) is to determine and understand genetic alterations in individual tumors in order to deliver precision medicine to individual cancer patients. The consortium brings together prominent cancer research groups from seven research institutions in the Netherlands. You will contribute genomics expertise to various collaborations within this consortium and be involved in whole genome sequencing and RNA-seq data analysis and interpretation of tumor and engineered/tumor organoid samples. You will also develop novel tools to study mutational processes. The research is expected to provide fundamental insight into cancer-causing mutational processes and may ultimately contribute to the development of novel diagnostic approaches or therapeutic interventions for cancer. For the latter, you will closely work with scientist from the Center for Personalized Cancer Treatment (www.cpct.nl) and the Hartwig Medical Foundation (www.hartwigmedicalfoundation.nl).
The Section of Genetics (http://www.umcutrecht.nl/en/Research/Research-centers/Center-for-Molecular-Medicine/Section-Genetics) of the Center for Molecular Medicine uses genomics and bioinformatics approaches to understand the genetic basis of disease. Expertise and state-of-the-art infrastructure is available for next-generation DNA and RNA sequencing, single molecule sequencing, genotyping, metabolomics, bioinformatics and a broad range of model systems, including patient-derived primary cultures, iPS cells and organoid culturing. The Cuppen group (http://www.umcutrecht.nl/en/Research/Research-centers/Center-for-Molecular-Medicine/Section-Genetics/Cuppen) is a translational research group that investigates the causes and consequences of genetic variation. Variation in DNA sequences can have a large impact on disease or disease susceptibility, for example resulting in congenital disease or cancer. In recent years new technologies have emerged that allow us to determine the complete DNA sequence of individuals. We are using the latest DNA and RNA sequencing technologies for studying the basis of specific human diseases. Interpretation of alterations at the single base letter and structural level in both protein-coding and regulatory domains is one of the main challenges that we address using systematic integrative experimental and computational approaches. Furthermore, we are studying the origin and mechanisms by which de novo genetic variation is induced, either in the germline resulting in congenital disease or in somatic cells, resulting in cancer. Our research is performed in a highly collaborative fashion both within the group and with other research groups, clinical laboratories and researchers on a local, national and international level.
You should have a MSc degree in Bioinformatics/Computational Biology, or a MSc degree in Biology/Biomedical Sciences with a strong expertise in computational data analysis. Experience in handling next-generation sequencing data is required, as well as a strong affinity for large scale bioinformatic data analysis and cancer research.